• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice
Chronic kidney disease is common in patients with atrial fibrillation (AF) and is associated with heightened risks of stroke/systemic embolisation and bleeding. In this review we outline the evidence for AF stroke prevention in kidney disease, identify current knowledge gaps, and give recommendations for anticoagulation at various stages of chronic kidney disease.Overall, anticoagulation is underused. Warfarin use becomes increasingly difficult with advancing kidney disease, with difficulty maintaining international normalised ratio (INR) in therapeutic range, increased risk of intracranial and fatal bleeding compared to n...
Source: Heart, Lung and Circulation - November 3, 2022 Category: Cardiology Authors: Christopher Hammett, Sunil V. Badve, Peter G. Kerr, Huyen A. Tran, Benjamin K. Dundon, Sidney Lo, Andrew Wong, Joanne E. Joseph, Jenny Deague, Vlado Perkovic Tags: Review Source Type: research

708 Stroke Prevention by Non-vitamin K Oral Anticoagulant (NOAC) Agents in the Absence of Atrial Fibrillation: Meta-analysis of Randomized Controlled Trials
Anticoagulation to prevent stroke is a mainstay of atrial fibrillation (AF) management. Use of warfarin in sinus rhythm reduces stroke rates, but with an increase in bleeding. The efficacy and safety of NOACs has not been studied.
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: K. Lander, P. Thakeria, A. Ha, S. Nayyar Source Type: research

Quality of Warfarin Anticoagulation in Indigenous and Non-Indigenous Australians With Atrial Fibrillation
Studies have shown that suboptimal anticoagulation quality, as measured by time in therapeutic range (TTR), affects a significant percentage of patients with atrial fibrillation (AF). However, TTR has not been previously characterised in Indigenous Australians who experience a greater burden of AF and stroke.
Source: Heart, Lung and Circulation - November 27, 2019 Category: Cardiology Authors: Mau T. Nguyen, Celine Gallagher, Bradley M. Pitman, Mehrdad Emami, Kadhim Kadhim, Jeroen M. Hendriks, Melissa E. Middeldorp, Kurt C. Roberts-Thomson, Rajiv Mahajan, Dennis H. Lau, Prashanthan Sanders, Christopher X. Wong Tags: Original Article Source Type: research

Quality of Warfarin Anticoagulation in  Indigenous and Non-Indigenous Australians With Atrial Fibrillation
Studies have shown that suboptimal anticoagulation quality, as measured by time in therapeutic range (TTR), affects a significant percentage of patients with atrial fibrillation (AF). However, TTR has not been previously characterised in Indigenous Australians who experience a greater burden of AF and stroke.
Source: Heart, Lung and Circulation - November 27, 2019 Category: Cardiology Authors: Mau T. Nguyen, Celine Gallagher, Bradley M. Pitman, Mehrdad Emami, Kadhim Kadhim, Jeroen M. Hendriks, Melissa E. Middeldorp, Kurt C. Roberts-Thomson, Rajiv Mahajan, Dennis H. Lau, Prashanthan Sanders, Christopher X. Wong Tags: Original Article Source Type: research

Trends in the Use of Warfarin and Novel Oral Anticoagulants in Australia, 2013 to 2017
Background: In 2013, novel oral anticoagulants (NOACs) were added to the PBS as alternatives to warfarin for stroke prevention in atrial fibrillation (AF). Aim of this study is to examine changes in the use of oral anticoagulants (OACs) since the introduction of NOACs.
Source: Heart, Lung and Circulation - June 23, 2019 Category: Cardiology Authors: A. Dina, T. Akindele Tags: 231 Source Type: research

Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation
Non-vitamin K antagonist oral anticoagulants (NOACs) have been recommended as preferred options for stroke prevention in patients with atrial fibrillation (AF) versus warfarin by guidelines worldwide.
Source: Heart, Lung and Circulation - March 19, 2019 Category: Cardiology Authors: Piyameth Dilokthornsakul, Surakit Nathisuwan, Rungroj Krittayaphong, Aurauma Chutinet, Unchalee Permsuwan Tags: Original Article Source Type: research

NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia
The management of stroke risk in patients with non-valvular atrial fibrillation has changed over the past few years. This change has occurred due to the introduction of novel oral anticoagulants (NOACs) such as apixaban, rivaroxaban and dabigatran for the management of non-valvular atrial fibrillation. These agents have shown comparable stroke risk reduction to warfarin in large international multicentre trials [1 –3]. This has changed the clinical practice of many treating physicians since their introduction from 2011 to 2013.
Source: Heart, Lung and Circulation - March 22, 2018 Category: Cardiology Authors: Derk Pol, Claire Curtis, Satish Ramukumar, Logan Bittinger Tags: Brief Communication Source Type: research

NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.
The management of stroke risk in patients with non-valvular atrial fibrillation has changed over the past few years. This change has occurred due to the introduction of novel oral anticoagulants (NOACs) such as apixaban, rivaroxaban and dabigatran for the management of non-valvular atrial fibrillation. These agents have shown comparable stroke risk reduction to warfarin in large international multicentre trials [1 –3]. This has changed the clinical practice of many treating physicians since their introduction from 2011 to 2013.
Source: Heart, Lung and Circulation - March 22, 2018 Category: Cardiology Authors: Derk Pol, Claire Curtis, Satish Ramukumar, Logan Bittinger Tags: Brief Communication Source Type: research

Identifying Warfarin Control With Stroke and Bleed Risk Scores
Warfarin decreases stroke risk in atrial fibrillation patients, with efficacy and safety impacted by the quality of warfarin control, as measured by time in therapeutic range (TTR). Stroke and bleed risk scores are calculated prior to commencing warfarin, so it would be beneficial if these scores also identified likely warfarin control. Some studies have investigated CHADS2, CHA2DS2VASc, and HASBLED individually for this purpose, but application of all scores to diverse ethnic populations and at sites with differing overall control has not been investigated.
Source: Heart, Lung and Circulation - November 28, 2017 Category: Cardiology Authors: Nijole Bernaitis, Chi Keong Ching, Tony Badrick, Shailendra Anoopkumar-Dukie Tags: Brief Communication Source Type: research

An Update on Anticoagulation in Atrial Fibrillation
Cerebrovascular accidents or strokes related to atrial fibrillation (AF) are potentially preventable with anticoagulation. Until recently, warfarin was the only proven anticoagulant to be effective in stroke prevention, however the novel, direct acting oral anticoagulants (DOACs) are now available, triggering a paradigm shift in treatment philosophy. Today, physicians need to consider in which patients anticoagulation should not be used rather than, as in the past, deciding in which patients it should be used.
Source: Heart, Lung and Circulation - June 2, 2017 Category: Cardiology Authors: John Amerena, Daryl Ridley Tags: Review Source Type: research

Current Prescribing Trends for Atrial Fibrillation Anticoagulation in Australia
Introduction: Management of stroke risk in atrial fibrillation has changed over the last few years with the introduction of novel oral anticoagulants (NOACs) such as Apixaban, Rivaroxaban and Dabigatran. These agents are being increasingly prescribed secondary to the ease of use compared to warfarin which requires regular and ongoing INR monitoring.
Source: Heart, Lung and Circulation - July 27, 2016 Category: Cardiology Authors: D. Pol, V. Mutha, L. Bittinger Tags: 297 Source Type: research

Trends in Prescription of Novel Oral Anticoagulants (NOACs) and Warfarin in Australia 2010-2015
This study examines the rates of prescription of rivaroxaban, apixaban, dabigatran and warfarin over the period of July 2010 to June 2015.
Source: Heart, Lung and Circulation - July 27, 2016 Category: Cardiology Authors: A. Vlachadis Castles, I. Tsay, W. van Gaal Tags: 321 Source Type: research

Current Prescribing Trends for Atrial Fibrillation Anticoagulation in Australia
Introduction: Management of stroke risk in atrial fibrillation has changed over the last few years with the introduction of novel oral anticoagulants (NOACs) such as Apixaban, Rivaroxaban and Dabigatran. These agents are being increasingly prescribed secondary to the ease of use compared to warfarin which requires regular and ongoing INR monitoring.
Source: Heart, Lung and Circulation - July 26, 2016 Category: Cardiology Authors: D. Pol, V. Mutha, L. Bittinger Tags: 297 Source Type: research

Pages: 1  2